Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Edward M. KayeIndependent Director | -2,93k | 223,17k | Verkauf | 76,09 | 10,28k | -22,19% |
| 2026-06-01 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 762,30k | Derivative Exercise and Sale | 23,26 - 74,08 | 1,59k | - |
| 2026-06-01 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 370,40k | Verkauf | 74,08 | 15,78k | -24,06% |
| 2026-05-27 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 579,08k | Verkauf | 77,21 | 239,78k | -3,03% |
| 2026-05-19 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 237,62k | Derivative Exercise and Sale | 7,80 - 75,69 | 98,66k | - |
| 2026-05-14 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 584,40k | Verkauf | 77,92 | 247,28k | -2,94% |
| 2026-05-05 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 243,50k | Derivative Exercise and Sale | 7,80 - 77,37 | 98,66k | - |
| 2026-05-05 | Dr. Wendell D. WierengaIndependent Director | -4,03k | 252,40k | Derivative Exercise and Sale | 12,40 - 75,00 | 32,64k | - |
| 2026-05-05 | Mr. Sung H. LeeEVP & CFO | -23,91k | 1,84M | Verkauf | 76,87 | 2,15k | -91,74% |
| 2026-05-05 | Dr. John Tannahill HendersonIndependent Chairman | -20,00k | 1,37M | Derivative Exercise and Sale | 7,61 - 75,97 | 67,99k | - |
| 2026-05-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -11,33k | 432,01k | Derivative Exercise and Sale | 39,13 - 77,25 | 1,59k | - |
| 2026-05-01 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,86k | 434,01k | Derivative Exercise and Sale | 37,63 - 65,00 | 1,59k | - |
| 2026-04-30 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 600,00k | Derivative Exercise and Sale | 23,26 - 63,26 | 1,59k | - |
| 2026-04-29 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 447,15k | Verkauf | 59,62 | 254,78k | -2,86% |
| 2026-04-21 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 202,62k | Derivative Exercise and Sale | 7,80 - 65,69 | 98,66k | - |
| 2026-04-15 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -7,45k | 491,78k | Verkauf | 66,02 | 1,59k | -82,42% |
| 2026-04-15 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 490,35k | Verkauf | 65,38 | 262,28k | -2,78% |
| 2026-04-07 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -4,50k | 255,09k | Derivative Exercise and Sale | 7,80 - 65,21 | 98,66k | - |
| 2026-04-01 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 499,73k | Verkauf | 66,63 | 269,78k | -2,70% |
| 2026-03-31 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -3,64k | 236,54k | Verkauf | 65,00 | 9,04k | -28,71% |
| 2026-03-17 | Mr. Sung H. LeeEVP & CFO | -4,94k | 306,71k | Verkauf | 62,15 | 87,13k | -5,36% |
| 2026-03-17 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -10,47k | 650,68k | Verkauf | 62,07 - 62,15 | 14,61k | -41,76% |
| 2026-03-17 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -12,03k | 747,85k | Verkauf | 62,15 | 98,66k | -10,87% |
| 2026-03-17 | Mr. Robert I. BlumCEO, President & Director | -36,60k | 2,27M | Verkauf | 62,15 | 277,28k | -11,66% |
| 2026-03-16 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,71k | 104,30k | Verkauf | 61,03 | 23,15k | -6,88% |
| 2026-03-09 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -2,58k | 156,78k | Verkauf | 60,72 | 5,01k | -34,03% |
| 2026-03-09 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,91k | 176,51k | Verkauf | 60,72 | 86,38k | -3,26% |
| 2026-03-09 | Mr. Robert I. BlumCEO, President & Director | -7,93k | 481,57k | Verkauf | 60,72 | 242,85k | -3,16% |
| 2026-03-02 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 306,05k | Verkauf | 61,21 | 10,60k | -32,05% |
| 2026-03-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -886,00 | 21,26k | Derivative Exercise and Sale | 37,63 - 61,62 | 1,59k | - |
| 2026-02-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 580,05k | Derivative Exercise and Sale | 23,26 - 61,93 | 1,59k | - |
| 2026-02-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -886,00 | 21,68k | Derivative Exercise and Sale | 37,63 - 62,10 | 1,59k | - |
| 2026-01-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 555,30k | Derivative Exercise and Sale | 23,26 - 60,28 | 1,59k | - |
| 2026-01-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -913,00 | 56,69k | Verkauf | 62,09 | 1,59k | -36,51% |
| 2026-01-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -885,00 | 22,59k | Derivative Exercise and Sale | 37,63 - 63,16 | 1,59k | - |
| 2025-12-29 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,81k | 112,95k | Verkauf | 62,44 | 2,50k | -41,97% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | -2,94k | 184,08k | Sale to Issuer | 62,72 | 234,28k | -1,24% |
| 2025-12-22 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -1,02k | 63,72k | Sale to Issuer | 62,72 | 81,29k | -1,23% |
| 2025-12-22 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -675,00 | 42,34k | Sale to Issuer | 62,72 | 4,31k | -13,54% |
| 2025-12-22 | Mr. Sung H. LeeEVP & CFO | -805,00 | 50,49k | Sale to Issuer | 62,72 | 17,92k | -4,30% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | 40,81k | 272,18k | Derivative Exercise and Retained Stock | 6,67 | 225,69k | 22,07% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | -30,43k | 1,87M | Derivative Exercise and Sale | 6,67 - 68,18 | 225,69k | - |
| 2025-12-22 | Dr. Wendell D. WierengaIndependent Director | -20,00k | 1,17M | Derivative Exercise and Sale | 7,61 - 66,14 | 32,44k | - |
| 2025-12-16 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 111,41k | Derivative Exercise and Sale | 10,60 - 61,24 | 78,30k | - |
| 2025-12-08 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,04k | 27,96k | Derivative Exercise and Sale | 39,13 - 65,96 | 1,81k | - |
| 2025-12-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -52,49k | 1,69M | Derivative Exercise and Sale | 23,26 - 65,95 | 1,81k | - |
| 2025-12-03 | Mr. Sung H. LeeEVP & CFO | -1,56k | 101,43k | Sale to Issuer | 65,02 | 14,42k | -9,76% |
| 2025-12-03 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,37k | 88,95k | Sale to Issuer | 65,02 | 1,81k | -43,07% |
| 2025-12-03 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,06k | 133,81k | Sale to Issuer | 65,02 | 78,30k | -2,56% |
| 2025-12-03 | Mr. Robert I. BlumCEO, President & Director | -5,93k | 385,57k | Sale to Issuer | 65,02 | 184,88k | -3,11% |
| 2025-12-02 | Dr. John Tannahill HendersonIndependent Chairman | -8,75k | 471,63k | Derivative Exercise and Sale | 10,00 - 63,90 | 67,33k | - |
| 2025-12-02 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 117,24k | Derivative Exercise and Sale | 10,60 - 63,89 | 76,36k | - |
| 2025-12-01 | Dr. Edward M. KayeIndependent Director | -28,06k | 1,49M | Derivative Exercise and Sale | 12,40 - 66,72 | 2,64k | - |
| 2025-12-01 | Dr. Robert A. HarringtonIndependent Director | -2,15k | 143,62k | Verkauf | 66,80 | 11,21k | -16,09% |
| 2025-11-19 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 323,65k | Verkauf | 64,73 | 15,60k | -24,27% |
| 2025-11-18 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 122,87k | Derivative Exercise and Sale | 10,60 - 66,45 | 76,36k | - |
| 2025-11-11 | Dr. Edward M. KayeIndependent Director | -5,18k | 286,80k | Derivative Exercise and Sale | 9,66 - 65,08 | 2,64k | - |
| 2025-11-05 | Mr. Robert I. BlumCEO, President & Director | -2,00k | 0,00 | Other Disposition | - | 179,25k | -1,10% |
| 2025-11-04 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,30k | 112,34k | Derivative Exercise and Sale | 10,60 - 59,55 | 76,36k | - |
| 2025-10-30 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 314,30k | Verkauf | 62,86 | 181,25k | -2,68% |
| 2025-10-27 | Dr. Wendell D. WierengaIndependent Director | -4,38k | 212,98k | Derivative Exercise and Sale | 10,00 - 58,68 | 32,44k | - |
| 2025-10-21 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,11k | 100,24k | Derivative Exercise and Sale | 10,60 - 58,22 | 76,36k | - |
| 2025-10-07 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 99,92k | Derivative Exercise and Sale | 10,60 - 60,56 | 76,36k | - |
| 2025-10-06 | Dr. Edward M. KayeIndependent Director | -6,76k | 405,42k | Verkauf | 60,00 | 2,45k | -73,43% |
| 2025-10-01 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 275,25k | Verkauf | 55,05 | 191,25k | -2,55% |
| 2025-09-30 | Dr. Edward M. KayeIndependent Director | -6,70k | 368,76k | Verkauf | 55,08 | 9,20k | -42,11% |
| 2025-09-23 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 77,36k | Derivative Exercise and Sale | 10,60 - 49,28 | 76,36k | - |
| 2025-09-15 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 248,85k | Verkauf | 49,77 | 196,25k | -2,48% |
| 2025-09-09 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 81,38k | Derivative Exercise and Sale | 10,60 - 51,29 | 76,36k | - |
| 2025-09-02 | Dr. Edward M. KayeIndependent Director | -6,76k | 337,80k | Verkauf | 50,00 | 15,90k | -29,82% |
| 2025-09-02 | Dr. Robert A. HarringtonIndependent Director | -2,15k | 104,64k | Verkauf | 48,67 | 13,16k | -14,04% |
| 2025-09-02 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 243,80k | Verkauf | 48,76 | 201,25k | -2,42% |
| 2025-08-19 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 55,42k | Derivative Exercise and Sale | 10,60 - 38,31 | 76,36k | - |
| 2025-08-15 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 192,10k | Verkauf | 38,42 | 206,25k | -2,37% |
| 2025-08-05 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 51,48k | Derivative Exercise and Sale | 10,60 - 36,34 | 76,36k | - |
| 2025-07-29 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 182,25k | Verkauf | 36,45 | 211,25k | -2,31% |
| 2025-07-22 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 53,74k | Derivative Exercise and Sale | 10,60 - 37,47 | 76,36k | - |
| 2025-07-14 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 190,75k | Verkauf | 38,15 | 216,25k | -2,26% |
| 2025-07-08 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 46,32k | Derivative Exercise and Sale | 10,60 - 33,76 | 76,36k | - |
| 2025-07-01 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 167,75k | Verkauf | 33,55 | 221,25k | -2,21% |
| 2025-06-17 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 44,62k | Derivative Exercise and Sale | 10,60 - 32,91 | 76,36k | - |
| 2025-06-16 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 169,00k | Verkauf | 33,80 | 226,25k | -2,16% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
